(Q34315836)

English

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

Birte Yding Glenthøj

5

object named as

Birte Glenthoj

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

object named as

Peter Falkai

2

0 references

1

object named as

Alkomiet Hasan

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hans-Jürgen Möller

8

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jeffrey Lieberman

4

object named as

Jeffrey Lieberman

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Wagner Farid Gattaz

6

object named as

Wagner F Gattaz

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Thomas Wobrock

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Florence Thibaut

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

WFSBP Task force on Treatment Guidelines for Schizophrenia

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

6 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2-44

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Atypical antipsychotic induced weight gain: pathophysiology and management

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Orlistat in the treatment of psychopharmacologically induced weight gain.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Nizatidine for the treatment of patients with quetiapine-induced weight gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Impact of atypical antipsychotics on quality of life in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

How to grade categories of evidence.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The prevalence of the 65-kilodalton isoform of glutamic acid decarboxylase autoantibodies by glucose tolerance status in elderly patients from the cardiovascular health study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Weight loss in overweight patients maintained on atypical antipsychotic agents

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Tardive dyskinesia and new antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Compliance with medication regimens for mental and physical disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Second-generation antipsychotics and constipation: a review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Amantadine for weight gain associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Role of metformin for weight management in patients without type 2 diabetes

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The impact of topiramate (Topamax®) therapy on the development of aggressive and/or agitated behavior.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Interventions to reduce weight gain in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effect of amantadine on weight gain during olanzapine treatment

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Weight decline in patients switching from olanzapine to quetiapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-acting risperidone: a review of its use in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

ECT and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A pilot study of a weight management program with food provision in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Treatment of late-life schizophrenia with neuroleptics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Akathisia and second-generation antipsychotic drugs

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Vitamin B6 Treatment in Acute Neuroleptic-Induced Akathisia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

How to read and understand and use systematic reviews and meta-analyses

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Evidence-based pharmacotherapy of schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Tetrabenazine for the treatment of tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The effects of clozapine on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Deep brain stimulation: current and future clinical applications

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Costs and benefits of two doses of fluphenazine

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effects of an educational intervention on weight gain in patients treated with antipsychotics

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Novel antipsychotics in the long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The case for long-acting antipsychotic agents in the post-CATIE era.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Assessing QT interval prolongation and its associated risks with antipsychotics.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Clozapine-related seizures: experience with 5,629 patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Managing an effective treatment for neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Drug-induced prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Results of phase 3 of the CATIE schizophrenia trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

QTc and psychopharmacs: are there any differences between monotherapy and polytherapy

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Surgery for tardive dyskinesia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Treatment of severe tardive dystonia with pallidal deep brain stimulation.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Cognitive behavior therapy for weight gain

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Pallidotomy for tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Behavioural management of antipsychotic-induced weight gain: a review

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2012.739708

21 January 2018

Identifiers

10.3109/15622975.2012.739708

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34315836&oldid=1638453360"